SermorelinrctRCT2000

The GH response to low-dose bolus growth hormone-releasing hormone (GHRH(1-29)NH2) is attenuated in patients with longstanding post-irradiation GH insufficiency.

European journal of endocrinology

confidence

Key findings

GH response to bolus GHRH is attenuated in long-term survivors of childhood brain tumours, reflecting pituitary damage and/or chronic GHRH deficiency.

View source on PubMed (PMID 10754477) ↗

Sample size
10 (5 irradiated, 5 controls)
Population
Adult male long-term survivors of childhood brain tumours post cranial irradiation (>30Gy) and matched controls
Dosing
GHRH(1-29)NH2 IV bolus at 0.05, 0.15, and 1.0 microg/kg
Duration
Single stimulation test sessions; subjects 13.7 years post-radiotherapy
Route
intravenous
Blinding
not_reported
Controls
active_comparator
Drug class
GHRH analog

Measured endpoints

  • Peak GH concentration (0.15 microg/kg GHRH)Decreasedhormonal
    significanteffect: median peak Irradiated 4.5 mU/l vs Controls 37.4 mU/l
  • Peak GH concentration (1.0 microg/kg GHRH)Decreasedhormonal
    significanteffect: median peak Irradiated 4.8 mU/l vs Controls 15.2 mU/l
  • GH AUC response to increasing GHRH doses (irradiated subjects)Increasedhormonal
    significanteffect: median AUC 122 vs 179 vs 268 mU/l.min
Full abstract

Previous studies have suggested that post-irradiation GH insufficiency results from a loss of GHRH secretion, since many patients were able to release GH following exogenous GHRH stimulation. However, supramaximal doses of GHRH were used and the response may decline with time after radiotherapy. We re-evaluated the GHRH dose-response curve in patients post cranial irradiation and in controls. Randomized controlled study. Five adult male long-term survivors of childhood brain tumours (median age 21.8 years (18.4-26.7); 13.7 years (11.4-15.7) post-radiotherapy, >30Gy) and five matched controls were studied. An intravenous bolus of GHRH(1-29)NH(2) was administered in doses at the lower (0.05 microg/kg) and upper (0.15 microg/kg) range of the dose-response curves for young males, as well as the standard supramaximal dose (1. 0 microg/kg). GH was measured before stimulation, every 2min for the first hour and every 5min for the second hour. All studies were conducted in a random fashion. Significantly lower peak and area under the curve (AUC) GH concentrations occurred in the irradiated group using 0.15 microg/kg (median peak Irradiated, 4. 5mU/l vs median Controls, 37.4mU/l; P<0.01) and 1.0 microg/kg (median peak Irradiated, 4.8mU/l vs median Controls, 15.2mU/l; P<0. 05) GHRH(1-29)NH(2). In irradiated subjects there was an incremental rise in GH output with increasing doses of GHRH(1-29)NH(2 )(median AUC: 122mU/l.min vs 179mU/l.min vs 268mU/l.min; P=0.007) reflecting altered pituitary sensitivity and reduced responsiveness. The GH response to bolus GHRH(1-29)NH(2) is attenuated in adult long-term survivors of childhood brain tumours. This may reflect direct pituitary damage and/or the loss of the tropic effects of chronic GHRH deficiency.

Research information, not medical advice. StudyKit summarizes published studies to help you understand your protocol. It does not diagnose, treat, or replace a clinician. Talk to a qualified provider before changing anything you take.